Ultime prove

EudraCT Number: 2008-008246-20

Sponsor Protocol Number: ABR 25995

Start Date:

Sponsor Name: Radboud University Nijmegen Medical Center, Department of Anaesthesiology, Pain and Palliative Medic

Full Title: Evaluation of the efficacy and safety of sugammadex (Bridion) in children with renal failure.

Medical condition: Sugammadex is a selective relaxant binding agent, which is administered in case of a rocuronium-induced neuromuscular block, during general anaesthesia. The aim of the trial is to investigate the u...

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10038443	Renal failure and impairment	HLT
	9.1		10009119	Chronic renal failure	LLT
	9.1		10014647	End stage renal failure	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: NL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2019-003117-33

Sponsor Protocol Number: Pevonedistat-2002

Start Date:

Sponsor Name: Millennium Pharmaceuticals, Inc.

Full Title: A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unf...

Medical condition: Acute Myeloid Leukemia (AML)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10000886	Acute myeloid leukemia	LLT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024330	Leukemia acute	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024348	Leukemia myelogenous	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PL (Ongoing) IT (Ongoing) FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-002443-38

Sponsor Protocol Number: C0371006

Start Date:

Sponsor Name: Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Full Title: Phase 3 open-label study to evaluate efficacy, safety, and tolerability of FIX gene transfer with fidanacogene elaparvovec (PF-06838435) in pediatric male participants

Medical condition: moderately severe to severe hemophilia B (FIX:C≤2%)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004850	10060614	Hemophilia B (Factor IX)	LLT

Population Age: Adolescents, Under 18

Gender: Male

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2015-005537-50

Sponsor Protocol Number: 15/BWH/P061

Start Date:

Sponsor Name: Birmingham Women's Hospital

Full Title: High Or Low Dose Syntocinon® for delay in labour: the HOLDS trial

Medical condition: Approximately a third of women become delayed in their first labours and are given intravenous oxytocin in an attempt to increase their uterine contractions, increase spontaneous vaginal birth and ...

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10036585 - Pregnancy, puerperium and perinatal conditions	10000153	Abnormal labour	PT

Population Age: Adolescents, Under 18, Adults

Gender: Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2006-000441-19

Sponsor Protocol Number: H3E-EW-S098

Start Date:

Sponsor Name: Eli lilly and Company Limited

Full Title: A randomised Phase II study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-vinorelbine, in Anthracycline and Taxane pretreated Advanced Breast cancer patients.

Medical condition: advanced breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.0		10006285		LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DE (Completed) ES (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2015-003424-31

Sponsor Protocol Number: I4V-MC-JAGA

Start Date:

Sponsor Name: Eli Lilly and Company

Full Title: Treatment of Conditions Expected to Benefit from JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis

Medical condition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Syndrome

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2010-022046-25

Sponsor Protocol Number: Zellweger

Start Date:

Sponsor Name: Department of Pediatric Gastroenterology, Academic Medical Centre

Full Title: Cholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects.

Medical condition: Peroxisomal biogenesis disorder Synonym: Zellweger spectrum disorder This syndrome encompasses a spectrum of severity in symptoms Previously the disorder was subdivided into three disorders based...

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10053706	Zellweger syndrome	LLT
	12.1		10038275	Refsum's disease	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2018-003863-67

Sponsor Protocol Number: FME_2018_9

Start Date:

Sponsor Name: Fondation Ophtalmologique Adolphe de Rothschild

Full Title: Multicenter randomized controlled trial on the interest of intravitreal injections of anti-VEGF as initial and adjuvant treatment in Coats disease

Medical condition: Coats disease

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2011-003295-37

Sponsor Protocol Number: V00034CR3121B

Start Date:

Sponsor Name: PIERRE FABRE MEDICAMENT

Full Title: Efficacy of the V0034CR01B emollient on xerosis in children with atopic dermatitis. Randomised, vehicle-controlled, parallel-groups, double-blind study with an open label extension

Medical condition: xerosis in children with atopic dermatitis

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.0	10040785 - Skin and subcutaneous tissue disorders	10003639	Atopic dermatitis	LLT

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: FR (Completed) EE (Completed) LT (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2015-003670-32

Sponsor Protocol Number: REFLECT

Start Date:

Sponsor Name: Medical Center - University of Freiburg

Full Title: A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB)

Medical condition: Recessive dystrophic epidermolysis bullosa (RDEB)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10014989	Epidermolysis bullosa	PT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: DE (Completed) AT (Completed)

Trial results: View results

Ultime prove

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici